JNJ-47910382
/ J&J
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 25, 2012
Study in HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of JNJ-47910382
(clinicaltrials.gov)
- P1, N=40; Not yet recruiting; New P1 trial
New P1 trial • Hepatitis C Virus
April 20, 2019
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
(clinicaltrials.gov)
- P1; N=8; Terminated; Sponsor: Janssen R&D Ireland; N=18 ➔ 8; Recruiting ➔ Terminated; Because of many competing trials using the same mechanism of action, but being further advanced in development
Clinical • Enrollment change • Trial termination
1 to 2
Of
2
Go to page
1